Conatus Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, CNAT, Conatus Pharmaceuticals Inc, priceseries

Conatus Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.59
Close
0.56
High
0.59
Low
0.54
Previous Close
0.56
Daily Price Gain
0.00
YTD High
156.70
YTD High Date
Jan 10, 2014
YTD Low
0.45
YTD Low Date
May 21, 2020
YTD Price Change
-92.94
YTD Gain
-99.41%
52 Week High
156.70
52 Week High Date
Jan 10, 2014
52 Week Low
0.45
52 Week Low Date
May 21, 2020
52 Week Price Change
-92.94
52 Week Gain
-99.41%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 23. 2016
44.30
Jan 6. 2017
48.91
8 Trading Days
10.42%
Link
LONG
Mar 24. 2017
48.20
Apr 5. 2017
53.80
8 Trading Days
11.63%
Link
LONG
Apr 6. 2017
56.00
May 3. 2017
77.60
18 Trading Days
38.57%
Link
LONG
Jun 23. 2017
51.00
Jul 17. 2017
64.36
15 Trading Days
26.19%
Link
LONG
Dec 15. 2017
42.70
Dec 28. 2017
45.97
8 Trading Days
7.66%
Link
LONG
Mar 2. 2018
61.20
Mar 14. 2018
64.94
8 Trading Days
6.11%
Link
LONG
May 29. 2018
37.70
Jun 21. 2018
50.51
17 Trading Days
33.99%
Link
LONG
Aug 22. 2018
41.30
Sep 5. 2018
50.57
9 Trading Days
22.46%
Link
LONG
Sep 18. 2018
47.00
Sep 28. 2018
53.09
8 Trading Days
12.96%
Link
LONG
Dec 31. 2018
17.30
Jan 14. 2019
18.48
9 Trading Days
6.79%
Link
LONG
May 5. 2020
4.73
May 6. 2020
5.06
1 Trading Days
7.13%
Link
Company Information
Stock Symbol
CNAT
Exchange
NasdaqGM
Company URL
http://www.conatuspharma.com
Company Phone
(858) 376-2600
CEO
Steven J. Mento
Headquarters
California
Business Address
16745 WEST BERNARDO DRIVE, Suite 200, San Diego, CA 92127
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001383701
About

Conatus Pharmaceuticals, Inc. is a biotechnology company that engages in the development and commercialization of medicines to liver diseases treatment. It focuses in development of Emricasan, orally active protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death or apoptosis for the interruption of progress of liver disease. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in Dan Diego, CA.

Description

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading